Secondary Hyperparathyroidism

Parathyroidectomy prior to kidney transplantation is associated with a lower risk for severe postoperative complications compared with calcimimetic treatment, according to investigators.

Patients undergoing parathyroidectomy for SHPT that is refractory to calcimimetics frequently show significant enlargement of the parathyroid glands as well as histopathologic alterations, new findings suggest.

In a study, investigators tested etelcalcetide combination therapies in patients on maintenance hemodialysis who have secondary hyperparathyroidism.

The selective vitamin D analog and calcimimetic were both beneficial in decreasing parathyroid hormone levels, according to the authors of a new meta-analysis.

According to a study, 1 in 5 dialysis facilities might face financial losses if calcimimetics are included in the payment bundle, and providers may feel pressured to reduce calcimimetic use.

The latest meta-analysis, however, confirms that the calcimimetic improves biochemical parameters, such as parathyroid hormone levels.

Investigators analyzed data from 36 randomized trials comparing cinacalcet, etelcalcetide, and evocalcet with placebo.

Hemodialysis patients with secondary hyperparathyroidism have higher rates of mortality, readmission, and reoperation than those with primary hyperparathyroidism, so parathyroidectomy is associated with higher costs, according to investigators.

Parathyroid hormone levels declined in the 6 months after patients received microwave ablation, a meta-analysis finds.